Status and phase
Conditions
Treatments
About
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Main Study Only:
Open-Label Rollover
Exclusion criteria
A reduced list of inclusion and exclusion criteria apply to participants in the open-label rollover extension.
Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
700 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Akero Study Director
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal